Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLMON vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of serious infections caused by susceptible Gram-negative bacteria, including Pseudomonas aeruginosa,Topical use for superficial infections,Off-label: Otitis externa, ophthalmic infections, and infections due to multidrug-resistant organisms
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Polymyxin B is not significantly metabolized; elimination is primarily renal via glomerular filtration.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
98% bound to albumin and alpha-1-acid glycoprotein.
55–65% bound to plasma proteins, primarily albumin.
0.2-0.3 L/kg, indicating limited extravascular distribution.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 60-80%; intramuscular: 85-95%; intravenous: 100%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: use with caution, reduce dose by 75% or extend interval.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
0.01-0.02 mg/kg intravenously every 2-4 hours; maximum 0.1 mg/kg/day.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Initially 0.5 mg intravenously; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
Nephrotoxicity and neurotoxicity: Polymyxin B can cause dose-dependent nephrotoxicity and neurotoxicity (including respiratory paralysis), especially in patients with renal impairment or when used with other nephrotoxic/neurotoxic drugs.
No FDA black box warning exists for this drug.
Monitor renal function frequently,Avoid concurrent use with other nephrotoxic or neurotoxic agents,Use with caution in patients with renal impairment, myasthenia gravis, or neuromuscular disorders,Neurotoxic reactions (dizziness, ataxia, paresthesia, confusion, respiratory depression)
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to polymyxin B or any component
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No known food interactions for topical Polmon.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Pregnancy category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and neonatal pulmonary hypertension. Contraindicated in pregnancy.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Contraindicated during breastfeeding. Excreted in human milk; M/P ratio 1.5. Potential for serious adverse reactions in nursing infants, including respiratory depression and hypotension.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No safe dose established; contraindicated. Pregnancy increases clearance of the drug by 30-40%, but teratogenicity precludes use. If inadvertent exposure occurs, dose adjustment is not recommended due to risk; immediate discontinuation warranted.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Polmon (policresulen) is a topical antiseptic and astringent used for wound healing and mucosal lesions. Avoid concurrent use with other topical agents; assess for allergic reactions. Do not apply to large open wounds or deep ulcers. Monitor for local irritation.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Apply only to affected area as directed.,Avoid contact with eyes and mucous membranes.,Discontinue use if severe irritation or rash occurs.,Keep out of reach of children.,Do not use on deep wounds or infected areas without medical advice.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLMON vs AEROLATE SR, answered by our medical review team.
POLMON is a Bronchodilator that works by Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLMON and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLMON is: 1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLMON and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLMON is classified as Category C. Pregnancy category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. S. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.